CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight

Lasme-celPositive

AI Analysis

Summary

Market analysis forecasts CAR T-cell therapy for acute lymphoblastic leukemia to grow at a CAGR of 6.8% through 2036, driven by emerging therapies including Lasme-cel (UCART22) and expanded R&D activities.

Importance:2/10

Sentiment:

0.50

CAR T-cell therapyAcute Lymphoblastic LeukemiaMarket forecastPipeline expansionEmerging therapies

Read the original article

Published by PR Newswire Pharma on August 12, 2026 2:31 PM

Read Original